

Cytokeratin 5 (CK5)

Concentrated and Prediluted Rabbit Monoclonal Antibody
901-430-060223

BIOCARE
M E D I C A L

Catalog Number:	CME 430 A, B	PME 430 AA	VLTR 430 G20
Description:	0.1, 0.5 mL, conc.	6.0 mL, RTU	20 mL, RTU
Dilution:	1:100	Ready-to-use	Ready-to-use
Diluent:	Renoir Red	N/A	N/A

Intended Use:

For In Vitro Diagnostic Use

Cytokeratin 5 (CK5) [EP42] is a rabbit monoclonal antibody that is intended for laboratory use in the qualitative identification of cytokeratin 5 protein by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human tissues. The clinical interpretation of any staining or its absence should be complemented by morphological studies using proper controls and should be evaluated within the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

Summary and Explanation:

CK5 is a type II intermediate filament protein that is expressed in active basal layers of most stratified squamous epithelia. Studies have shown CK5/6 to be a specific marker for lung squamous carcinoma and mostly negative for lung adenocarcinoma. In a published study, rabbit monoclonal CK5 antibody was compared to mouse monoclonal CK5/6. CK5 was 84% sensitive and 100% specific for lung SqCC when compared to CK5/6 (80% sensitivity and 97% specificity) (2,3). According to studies, CK6 mRNA has been detected in lung adenocarcinomas and thus CK5 alone, may be a more specific marker than CK5/6.

The CK5 predilute has been optimized for lung squamous cell carcinoma; other tumors have not been tested.

CK5 tissue distribution is in many non-keratinizing stratified squamous epithelia such as tongue mucosa, basal epithelia hair follicles, trachea, as well as basal cells in prostate glands and myoepithelial cells in mammary glands. CK5 is also expressed in most epithelial and biphasic mesotheliomas (6).

Principle of Procedure:

Antigen detection in tissues and cells is a multi-step immunohistochemical process. The initial step binds the primary antibody to its specific epitope. After labeling the antigen with a primary antibody, a one-step or two-step detection procedure can be applied. A one-step procedure will feature an enzyme labeled polymer that binds the primary antibody. A two-step procedure will feature a linker antibody added to bind to the primary antibody. An enzyme-labeled polymer is then added to bind the linker antibody. These detections of the bound antibodies are evidenced by a colorimetric reaction.

Source: Rabbit monoclonal

Species Reactivity: Human, others not tested

Clone: EP42 (previously known as EP1601Y)

Isotype: IgG

Protein Concentration: Call for lot specific Ig concentration.

Epitope/Antigen: C-terminal region of human CK5

Cellular Localization: Cytoplasmic

Positive Tissue Control: Lung squamous cell carcinoma, some breast cancers, or normal prostate or skin

Known Applications:

Immunohistochemistry (formalin-fixed paraffin-embedded tissues)

Supplied As: Buffer with protein carrier and preservative

Storage and Stability:

Store at 2°C to 8°C. The product is stable to the expiration date printed on the label, when stored under these conditions. Do not use after expiration date. Diluted reagents should be used promptly; any remaining reagent should be stored at 2°C to 8°C.

Protocol Recommendations (VALENT® Automated Slide Staining Platform):

VLTR430 is intended for use with the VALENT. Refer to the User Manual for specific instructions for use. Protocol parameters in the Protocol Manager should be programmed as follows:

Deparaffinization: Deparaffinize for 8 minutes with Val DePar.

Pretreatment: Perform heat retrieval at 98°C for 60 minutes using Val AR-Lo pH, 5X (use at 1X).

Peroxidase Block: Block for 5 minutes with Val Peroxidase Block.

Protein Block (Optional): Incubate for 10-20 minutes with Val Background Block.

Primary Antibody: Incubate for 30 minutes.

Secondary: N/A

Linker: Incubate for 10 minutes with Val Universal Linker.

Polymer: Incubate for 20 minutes with Val Universal Polymer.

Chromogen: Incubate for 5 minutes with Val DAB.

Counterstain: Counterstain for 5 minutes with Val Hematoxylin.

Protocol Recommendations (intelliPATH FLX® and manual use):

Peroxide Block: Block for 5 minutes with Peroxidized 1.

Pretreatment: Perform heat retrieval using Diva Decloaker. Refer to the Diva Decloaker data sheet for specific instructions.

Protein Block (Optional): Incubate for 5-10 minutes at RT with Background Punisher.

Primary Antibody: Incubate for 30 minutes at RT.

Probe: N/A

Polymer: Incubate for 30 minutes at RT with a secondary-conjugated polymer.

Chromogen: Incubate for 5 minutes at RT with Biocare's DAB - OR - Incubate for 5-7 minutes at RT with Warp Red.

Counterstain:

Counterstain with hematoxylin. Rinse with deionized water. Apply Tacha's Bluing Solution for 1 minute. Rinse with deionized water.

Technical Note:

This antibody, for intelliPATH FLX and manual use, has been standardized with MACH 4 detection system. Use TBS for washing steps.

Limitations:

The optimum antibody dilution and protocols for a specific application can vary. These include, but are not limited to fixation, heat-retrieval method, incubation times, tissue section thickness and detection kit used. Due to the superior sensitivity of these unique reagents, the recommended incubation times and titers listed are not applicable to other detection systems, as results may vary. The data sheet recommendations and protocols are based on exclusive use of Biocare products. Ultimately, it is the responsibility of the investigator to determine optimal conditions.

Quality Control:

Refer to CLSI Quality Standards for Design and Implementation of Immunohistochemistry Assays; Approved Guideline-Second edition (I/LA28-A2). CLSI Wayne, PA, USA (www.clsi.org). 2011.

Precautions:

1. This antibody contains less than 0.1% sodium azide. Concentrations less than 0.1% are not reportable hazardous materials according to U.S. 29 CFR 1910.1200, OSHA Hazard communication and EC Directive 91/155/EC. Sodium azide (NaN₃) used as a preservative is toxic if

Cytokeratin 5 (CK5)

Concentrated and Prediluted Rabbit Monoclonal Antibody
901-430-060223

BIOCARE
M E D I C A L

Precautions Cont'd:

ingested. Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. Upon disposal, flush with large volumes of water to prevent azide build-up in plumbing. (Center for Disease Control, 1976, National Institute of Occupational Safety and Health, 1976) (8)

2. Specimens, before and after fixation, and all materials exposed to them should be handled as if capable of transmitting infection and disposed of with proper precautions. Never pipette reagents by mouth and avoid contacting the skin and mucous membranes with reagents and specimens. If reagents or specimens come in contact with sensitive areas, wash with copious amounts of water. (9)

3. Microbial contamination of reagents may result in an increase in nonspecific staining.

4. Incubation times or temperatures other than those specified may give erroneous results. The user must validate any such change.

5. Do not use reagent after the expiration date printed on the vial.

6. The SDS is available upon request and is located at <http://biocare.net>.

Troubleshooting:

Follow the antibody specific protocol recommendations according to data sheet provided. If atypical results occur, contact Biocare's Technical Support at 1-800-542-2002.

References:

1. Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, Napsin A, p63, and CK5/6. *Am J Surg Pathol.* 2011 Jan; 35(1):15-25.

2. Tacha D, Yu C, Haas T. TTF-1, Napsin A, p63, TRIM29, Desmoglein-3 and CK5: An Evaluation of Sensitivity and Specificity and Correlation of Tumor Grade for Lung Squamous Cell Carcinoma vs. Lung Adenocarcinoma. *Mod Pathol.* 2011 Feb; 24 (Supplement 1s):425A.

3. Tacha D, Zhou D, Henshall-Powell RL. Distinguishing Adenocarcinoma from Squamous Cell Carcinoma in Lung Using Double Stains p63+ CK5 and TTF-1 + Napsin A. *Mod Pathol.* 2010 Feb; 23 (Supplement 1s): 414A.

4. Terry J, *et al.* Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. *Am J Surg Pathol.* 2010 Dec; 34(12):1805-11.

5. Kargi A, Gurel D, Tuna B. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. *Appl Immunohistochem Mol Morphol.* 2007 Dec; 15(4):415-20.

6. Miettinen M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. *Am J Surg Pathol.* 2003 Feb; 27(2):150-8.

7. Bocker W, *et al.* Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. *Lab Invest.* 2002 Jun; 82 (6):737-46.

8. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 "Decontamination of Laboratory Sink Drains to Remove Azide Salts."

9. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.

Produced using Abcam's RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.



60 Berry Drive
Pacheco, CA 94553
USA



EC REP EMERGO EUROPE

Westervoortsedijk 6k
6827 AT Arnhem
The Netherlands